Occupation: Research House
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants.
Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries.
Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Run by a team of highly experienced professionals, our aim is to provide the research of choice for companies, investment banks and institutional investors. We provide independent reports, forecasts and valuations on each company we cover. We help clients gain access to investors, and facilitate feedback from the investment community on companies, their management and strategies. Our research strives to be objective, insightful, financially rigorous, readable and timely.
Web Address: http://www.edisongroup.com
280 High Holborn
Tel: Tel: +44 (0)20 3077 5700
OTC Markets Group (OTCQX: OTCM) provides regulated marketplaces offering a cost-effective solution for targeting US investors. Q214 gross revenues rose 15% compared with Q213, driven by a 41% increase in Market Data Licensing revenue from re-pricing and an increase in subscribers. This led to a 41% increase in operating profits and a 13% y-o-y increase in net income. More initiatives should produce revenue growth in…
After meetings with the FDA and several European national regulatory agencies, Onconova has informed the investment community that it will pursue an indication of rigosertib IV in patients who are primary hypomethylating agents (HMA) failures, with the detailed pivotal trial design to be unveiled in Q414. We consider this a positive first step of rigosertib IV’s comeback from the failure of meeting the primary endpoint…
Comvita is a natural health products manufacturer and marketer focused on manuka honey, bee products and fresh olive leaf extract. It sells a range of manuka honey-based health products via a range of distribution and sales channels, and has an exclusive licensing agreement with Derma Sciences for medical-grade manuka honey based products to the professional wound care market. Our valuation of the company is NZ$4.57…
Tourism Holdings (THL) is a New Zealand-based provider of tourism products for the ‘roam free’ free independent traveller (FIT) market. It has operations in New Zealand, Australia and the US. Its main product is motorhome rental and it also offers attractions and guided tours in New Zealand. THL has a rejuvenated board and is on a journey to restore return on capital employed (ROCE) to…
A weak trading environment and overruns on fixed-price contracts resulted in Q2 revenues and EBITDA below expectations; we reduce our FY estimates. Management is focused on driving the top line and acquisitions are being considered – it plans a €4m equity placing. With current sub-optimal consultant utilisation, revenue growth should quickly result in expanding EBITA margin, key to improving the low EV/sales valuation.